{"id":225633,"date":"2026-09-01T12:32:51","date_gmt":"2026-09-01T07:02:51","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=225633"},"modified":"2026-09-01T12:32:52","modified_gmt":"2026-09-01T07:02:52","slug":"gland-pharma-overvalued-or-undervalued","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gland-pharma-overvalued-or-undervalued\/","title":{"rendered":"Is Gland Pharma Overvalued or Undervalued Right Now?"},"content":{"rendered":"
<\/div>\n

Gland Pharma CMP Rs 2,894.00 (31 Aug 2026), up 0.21%. PE 42.18 vs industry PE 38.07. ROE 9.92%. 52W range Rs 1,573.60 to Rs 3,039.80.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Gland Pharma trades at a price to earnings ratio of 42.18 against an industry average of 38.07, which puts the stock close to fair value on a simple multiple basis rather than clearly overvalued or undervalued. The company’s 9.92% return on equity and Rs 627.88 book value per share fit broadly within its sector’s range. Whether Gland Pharma is overvalued or undervalued right now is less about a wide valuation gap and more about how its growth and margins evolve from here.<\/p>\n<\/div>\n

Is Gland Pharma overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 2,894.00, the stock trades roughly 4.8% below its 52 week high of Rs 3,039.80 and about 83.9% above its 52 week low of Rs 1,573.60.<\/p>\n

Gland Pharma’s share price moved up 0.21% in Monday’s session to Rs 2,894.00, against a market capitalisation of Rs 47,610 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n